To no great surprise, the U.K.’s health technology assessment body has found that the benefits of the first two approved ...

To no great surprise, the U.K.’s health technology assessment body has found that the benefits of the first two approved Alzheimer’s disease drugs are too small to justify the costs. Neither Kisunla ...

And more pharma news updates from Pharmalittle.

The UK's state-run health service said Thursday it will not offer two new treatments for Alzheimer's disease, citing high ...

NICE said it made every effort to support reimbursement for Kisunla and Leqembi, but found the medicines are “not good value ...

UK health technology assessor the National Institute for Health and Care Excellence (NICE) has announced that Japanese ...

A U.K. health agency said the Alzheimer's drugs Kisunla and Leqembi are not cost-effective, meaning they won't be offered through the NHS.

Dotinurad 4 mg/d is more effective in reducing serum urate levels than febuxostat 40 mg/d at week 24 in patients with gout, a ...

See here for Eisai (ESALF) stock analysis including Leqembi's EU approval, growth potential, and industry valuation amid ...

The oncology and neurology pharmaceutical company from Japan announced rolling layoffs back in February impacting 57 employees at its headquarters in Nutley, according to a 2025 WARN notice. The ...

NUTLEY, N.J., May 20, 2025 /PRNewswire/ -- Eisai announced today the presentation of clinical research across its oncology portfolio and pipeline during the 2025 American Society of Clinical ...

(Reuters) -The European Commission on Tuesday authorized the use of Eisai and Biogen's drug to treat some patients with mild cognitive impairment in the early stages of Alzheimer's disease, ending a ...